46.76
-3.06
(-6.14%)
As of 1:36:44 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
130,126
130,126
77,428
23,638
3,154
Cost of Revenue
13,368
13,368
9,302
2,133
599
Gross Profit
116,758
116,758
68,126
21,505
2,555
Operating Expense
382,261
382,261
252,483
200,662
172,614
Operating Income
-265,503
-265,503
-184,357
-179,157
-170,059
Net Non Operating Interest Income Expense
-5,892
-5,892
53
-1,172
447
Other Income Expense
11,139
11,139
190
-790
100,000
Pretax Income
-260,256
-260,256
-184,114
-181,119
-69,612
Tax Provision
346
346
564
--
--
Net Income Common Stockholders
-264,572
-264,572
-184,678
-181,119
-69,612
Diluted NI Available to Com Stockholders
-264,572
-264,572
-184,678
-181,119
-69,612
Basic EPS
-4.34
--
-3.20
-3.47
-1.40
Diluted EPS
-4.34
--
-3.20
-3.47
-1.40
Basic Average Shares
60,995.20
--
57,673.13
52,120.70
49,600.29
Diluted Average Shares
60,995.20
--
57,673.13
52,120.70
49,600.29
Total Operating Income as Reported
-265,503
-265,503
-184,357
-179,157
-170,059
Total Expenses
395,629
395,629
261,785
202,795
173,213
Net Income from Continuing & Discontinued Operation
-260,602
-260,602
-184,678
-181,119
-69,612
Normalized Income
-267,633
-267,633
-184,678
-181,119
-69,612
Interest Income
14,711
14,711
13,945
4,029
447
Interest Expense
20,603
20,603
13,892
5,201
--
Net Interest Income
-5,892
-5,892
53
-1,172
447
EBIT
-239,653
-239,653
-170,222
-175,918
-69,612
EBITDA
-238,090
-238,090
-168,464
-174,246
-68,454
Reconciled Cost of Revenue
13,368
13,368
9,302
2,133
599
Reconciled Depreciation
1,563
1,563
1,758
1,672
1,158
Net Income from Continuing Operation Net Minority Interest
-260,602
-260,602
-184,678
-181,119
-69,612
Total Unusual Items Excluding Goodwill
8,900
8,900
--
--
--
Total Unusual Items
8,900
8,900
--
--
--
Normalized EBITDA
-246,990
-246,990
-168,464
-174,246
-68,454
Tax Rate for Calcs
0
0
0
--
--
Tax Effect of Unusual Items
1,869
1,869
--
--
--
12/31/2021 - 10/9/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
XENE Xenon Pharmaceuticals Inc.
29.66
-3.42%
NUVL Nuvalent, Inc.
65.89
-3.56%
KRYS Krystal Biotech, Inc.
168.03
-5.67%
MLTX MoonLake Immunotherapeutics
37.22
-2.20%
SRRK Scholar Rock Holding Corporation
27.09
-11.76%
REPL Replimune Group, Inc.
7.41
-6.12%
KYMR Kymera Therapeutics, Inc.
22.23
-6.16%
MRUS Merus N.V.
37.78
-9.47%
PTGX Protagonist Therapeutics, Inc.
44.51
-4.29%
CRNX Crinetics Pharmaceuticals, Inc.
26.98
-6.55%